microdosing glp-1 dose One Size Does Not Fit All: Understanding Semaglutide for Diabetes in Multidose Pens Is It Smart For You

The experimental (hops) group also reported a reduction in cravings for savory and sweet foods compared to placebo [1]

In a development that could reshape diabetes care in Canada, the path has been cleared for generic versions of Ozempic and Wegovy to enter the Canadian market in 2026

Learn how GLP-1 medications like Wegovy and Zepbound impact digestion and gut motility

The weight loss market is undergoing a seismic shift as the focus moves from injectable peptides to oral small molecule GLP-1 receptor agonists, led by Eli Lillys promising candidate, orforglipron

This comprehensive review critically evaluates recent advances in BBRs anti-obesity pharmacology through three lenses: (1) preclinical and clinical evidence from randomized controlled trials, (2) molecular mechanisms underlying metabolic regulation, and (3) innovative strategies for pharmacokinetic optimization

Researchers at the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health, have discovered a gut-brain-immune network and posit a new gut-brain glucagon-like peptide 1 (GLP-1R) that controls inflammation across the body, a discovery which holds promise for understanding and treating metabolic diseases